尿β-D-半乳糖苷酶活性检测方法的建立及临床意义探讨

doi:10.3969/j.issn.1673-8640.2017.03.015

检验医学 ›› 2017, Vol. 32 ›› Issue (3): 219-223.DOI: 10.3969/j.issn.1673-8640.2017.03.015

• 技术研究与评价·论著 • 上一篇下一篇

尿β-D-半乳糖苷酶活性检测方法的建立及临床意义探讨

宋云霄¹, 邬建民², 张建华³, 姚莉韵³

1.上海市徐汇区中心医院检验科,上海 200031
2.上海市杨浦区精神卫生中心检验科,上海 200093
3.上海交通大学医学院化学教研室,上海 200025

收稿日期:2016-07-14 出版日期:2017-03-30 发布日期:2017-04-11
作者简介:null
作者简介：宋云霄,男,1973年生,副主任技师,主要从事临床生化检验工作。

Establishment on the determination method of urinary beta-D-galactosidase activity

SONG Yunxiao¹, WU Jianmin², ZHANG Jianhua³, YAO Liyun³

1. Department of Clinical Laboratory,Shanghai Xuhui Central Hospital,Shanghai 200031,China
2. Department of Clinical Laboratory,Shanghai Yangpu District Mental Health Center,Shanghai 200093,China
3. Department of Chemistry,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China

Received:2016-07-14 Online:2017-03-30 Published:2017-04-11

摘要/Abstract

摘要：

目的以2-氯-4-硝基苯基-β-D-半乳糖苷（CNP-GAL）为底物,建立测定尿β-D-半乳糖苷酶（GAL）活性的连续监测法,并探讨GAL在肾小管病变早期诊断中的临床意义。方法基于GAL能催化水解底物生成色原2-氯-4-硝基苯酚（CNP）的原理,对最适pH值、底物浓度、反应时间等条件进行研究,建立用于检测尿GAL的连续监测法,并用该法检测125例肾脏病变（30例继发性肾损伤、36例肾小管肾炎、25例肾癌、34例肾囊肿）患者及80名健康体检者（正常对照组）尿GAL活性。结果建立了检测尿GAL活性的连续监测法,采用柠檬酸缓冲液为最佳缓冲体系,酶促反应最适pH值为4.8,最适底物浓度为2.0 mmol/L。该法批内、批间平均变异系数（CV）分别为2.44%、4.47%,线性范围为3.2~25.6 U/L,当GAL<1.6 U/L时不能被检出。继发性肾损伤、肾小管肾炎、肾癌患者的尿GAL活性均明显高于正常对照组（P<0.05）,而肾囊肿患者的尿GAL活性无明显增高。结论建立的GAL活性连续监测法敏感性高,结果准确,操作简便,可用于肾小管疾病的早期诊断。

关键词: β-D-半乳糖苷酶, 2-氯-4-硝基苯基-β-D-半乳糖苷, 连续监测法, 肾小管病变

Abstract:

Objective To establish the continuous monitoring method for urinary beta-D-galactosidase （GAL） activity using 2-chloro-4-nitrophenyl-beta-D-galactosidase （CNP-GAL）as substrate,and to investigate the value of GAL in the early diagnosis of renal tubular lesion. Methods Based on the generation of color substance upon the hydrolysis of substrate into 2-chloro-4-nitrophenol（CNP）,the optimal pH value,substrate concentration,reaction time and so on were analyzed. The continuous monitoring method for urinary GAL activity was established. Urinary GAL activities in renal tubular lesion patients（30 cases of secondary renal injury,36 cases of tubal nephritis,25 cases of renal carcinoma and 34 cases of renal cyst） and 80 healthy subjects （healthy control group）were determined. Results The continuous monitoring method for urinary GAL activity was established using citric acid buffer solution. The enzyme optimal pH value was 4.8,the optimal substrate concentration was 2.0 mmol/L,and the within-run and between-run coefficients of variation（CV）were 2.44% and 4.47%. The linear range was 3.2- 25.6 U/L,which can not be determined at GAL<1.6 U/L. Urinary GAL activities in patients with secondary renal injury,tubal nephritis and renal carcinoma were higher than those in healthy control group（P<0.05）,and there was no difference in renal cyst patients. Conclusions The continuous monitoring method for urinary GAL activity has good sensitivity,precision and simplicity,which is suitable for the early diagnosis of renal tubular lesion.

Key words: Beta-D-galactosidase, 2-Chloro-4-nitrophenyl-beta-D-galactosidase, Continuous monitoring method, Renal tubular lesion

中图分类号:

Q555

宋云霄, 邬建民, 张建华, 姚莉韵. 尿β-D-半乳糖苷酶活性检测方法的建立及临床意义探讨[J]. 检验医学, 2017, 32(3): 219-223.

SONG Yunxiao, WU Jianmin, ZHANG Jianhua, YAO Liyun. Establishment on the determination method of urinary beta-D-galactosidase activity[J]. Laboratory Medicine, 2017, 32(3): 219-223.

图/表 9

参考文献 9

[1]	朱立华. 肾脏疾病的生化、免疫检测技术进展[J]. 中华检验医学杂志,2002,25(5):306-308.
[2]	YUEN C T,PRICE R G,CHATTAGOON L,et al.Colorimetric assays for N-acetyl-beta-D-glucosaminidase and beta-D-galactosidase in human urine using newly-developed omega-nitrostyryl substrates[J]. Clin Chim Acta,1982,124(2):195-204.
[3]	MARUHN D.Rapid colorimetric assay of beta-galactosidase and N-acetyl-glucosaminidase in human urine[J]. Clin Chim Acta,1976,73(3):453-461.
[4]	沈蓓. 尿微量清蛋白尿酶对糖尿病和高血压早期肾损伤的诊断价值[J]. 检验医学与临床,2008,5(5):552-553.
[5]	XU Y,GENDLER S J,FRANCO A.Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas[J]. J Exp Med,2004,199(5):707-716.
[6]	ROSSI F,CHARLTON C A,BLAU HM.Monitoring protein-protein interactions in intact eukaryotic cells by beta-galactosidase complementation[J]. Proc Natl Acad Sci U S A,1997,94(16):8405-8410.
[7]	王慧莲. 尿酶联合尿微量蛋白检测诊断糖尿病肾病[J]. 检验医学与临床,2013,10(6):712-713.
[8]	菅强,吴业宾,贾保民,等. 糖尿病患者尿NAG与微量清蛋白、GAL及血糖的关系[J]. 国际检验医学杂志,2012,33(12):1442-1443.
[9]	李招云,吴晓宇,赖卫强,等. 高血压病患者肾脏早期损害指标的探讨[J]. 中华检验医学杂志,2001,24(5):282-284.

自制GAL液（U/L）	0.1 mol/L 柠檬酸缓冲液	0.1 mol/L 醋酸缓冲液	0.1 mol/L 磷酸氢二钠柠檬酸钠缓冲液
5.3	5.3	4.3	4.2
10.1	10.4	9.3	9.4

自制GAL液（U/L）	0.1 mol/L 柠檬酸缓冲液	0.1 mol/L 醋酸缓冲液	0.1 mol/L 磷酸氢二钠柠檬酸钠缓冲液
5.3	5.3	4.3	4.2
10.1	10.4	9.3	9.4

GAL	批内		批间
GAL	x±s（U/L）	CV（%）	x±s（U/L）	CV（%）
高值	16.8±0.39	2.52	16.2±0.41	4.66
低值	5.23±0.12	2.36	5.20±0.23	4.28

GAL	批内		批间
GAL	x±s（U/L）	CV（%）	x±s（U/L）	CV（%）
高值	16.8±0.39	2.52	16.2±0.41	4.66
低值	5.23±0.12	2.36	5.20±0.23	4.28

时间（d）	4 ℃	37 ℃
3	0.003	0.003
7	0.003	0.004
14	0.003	0.005

尿β-D-半乳糖苷酶活性检测方法的建立及临床意义探讨

Establishment on the determination method of urinary beta-D-galactosidase activity

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 9

参考文献 9

相关文章 11

编辑推荐

Metrics

组别	例数	尿GAL
正常对照组	80	4.6±1.9
继发性肾损伤组	30	15.9±4.7^**
肾小管肾炎组	36	21.1±5.8^**
肾癌组	25	9.8±3.1^*
肾囊肿组	34	5.8±2.1

[1]	胡进访,吴雁,王白石,王旭. 双试剂速率法测定二胺氧化酶活性的研究[J]. 检验医学, 2013, 28(8): 711-715.
[2]	韩平治;丁进芳. 尿液N-乙酰-β-D-氨基葡萄糖苷酶连续监测法试剂盒性能评估[J]. 检验医学, 2000, 15(04): 240-241.
[3]	彭毅. 高酶活力标本动态分析有偏低假象的问题[J]. 检验医学, 1999, 14(2): 76-77.
[4]	周培芳；朱黎贤；李美英；杨文蔚. 上海市黄浦区健康人血清丙氨酸氨基转移酶水平的调查[J]. 检验医学, 1999, 14(1): 37-38.
[5]	孙虹；赵崇吉；马智. 正常儿童和成人血清LDH及同工酶谱分析[J]. 检验医学, 1998, 13(1): 3-3.
[6]	许金全. 不同性别年龄的血清ALP活力调查[J]. 检验医学, 1997, 12(2): 116-116.
[7]	朱玉胜. α－淀粉酶底物研究进展[J]. 检验医学, 1996, 11(4): 253-255.
[8]	唐玉海；刘丹；翟宁. 动力学连续监测法酶活力计算公式推导分析[J]. 检验医学, 1996, 11(2): 114-115.
[9]	. 上海医学检验杂志1995年第10卷主题索引[J]. 检验医学, 1995, 10(4): 258-261.
[10]	常伟；王念跃. 用连续监测法测定ALT应正确设置实验参数[J]. 检验医学, 1995, 10(1): 18-18.
[11]	王念跃；常伟. 血清甘氨酰脯氨酸二肽氨基肽酶连续监测法测定[J]. 检验医学, 1995, 10(1): 28-29.